Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03007030 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
A Phase 2 study of Malignant Mesothelioma and CD30-Positive Neoplastic Cells Present, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT03007030: Recruiting Phase 2 study of Malignant Mesothelioma and CD30-Positive Neoplastic Cells Present, sponsored by M.D. Anderson Cancer Center.
NCT03007030 is a Phase 2 study of Malignant Mesothelioma and CD30-Positive Neoplastic Cells Present that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 55 participants, below the 71-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03007030, a Phase 2 study of Malignant Mesothelioma and CD30-Positive Neoplastic Cells Present, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
A DCR of 50% or higher is considered as clinically significant. If the trial is not stopped early and all 50 patients are accrued, point estimate along with 95% credible interval will be provided. Logistic regression model will be utilized to assess the effect of patient prognostic factors on the response status if sufficient number of patients with stable disease or better response to the treatment are observed.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Brentuximab Vedotin
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
What NCT03007030 shows while recruiting
NCT03007030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 71-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (23% lower).
The record links to 2 conditions, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03007030 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03007030 about?
NCT03007030 is a clinical study titled "Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery". This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT03007030?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2017-04-05. Estimated completion is 2026-05-01.
What conditions does trial NCT03007030 study?
This clinical trial studies the following conditions: Malignant Mesothelioma, CD30-Positive Neoplastic Cells Present.
What interventions are being tested in trial NCT03007030?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03007030?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03007030 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03007030's enrollment target sits among peer trials
55 5th of 11 higher than 7 of 11 other Malignant Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
COMPLETED · Phase 2
-
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
COMPLETED · Phase 2
-
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
COMPLETED · Phase 2
-
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
COMPLETED · Phase 2
-
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
- NCT03317158 · 55 participants · Phase 1
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI